Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  mycophenolate mofetil
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 93 for your search:
Start Over
Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 40 to 60
Sponsor: Other
Protocol IDs: 2013-08, NCT01856803
Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 013-307, NCT02081755
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: OSHO#069, NCT01497002
Double Cord Versus Haploidentical (BMT CTN 1101)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: BMTCTN1101, 2U10HL069294-11, NCT01597778
the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 50
Sponsor: Other
Protocol IDs: GuangXi-AML- HSCT-2012-07, NCT01766375
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Phase: Phase III
Type: Supportive care
Status: Active
Age: 70 and under
Sponsor: NCI, Other
Protocol IDs: CASE6Z13, NCI-2013-01800, P30CA043703, NCT01951885
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: 1409.00, NCI-2010-00130, P30CA015704, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: EK 92062003, NCT00460447
Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 17 to 70
Sponsor: Other
Protocol IDs: 2067.00, NCI-2011-01352, R01AI041721, FHCRC-2067.00, 6364, NCT00622895
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, P30CA015704, FHCRC-2230.00, IR-6771, NCT00789776
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 montha to 70
Sponsor: Other
Protocol IDs: J1055, NA_00039823, NCT01203722
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 6 months to 85
Sponsor: Other
Protocol IDs: J1151, NA_00048378, NCT01342289
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: AMCPHO-SCT0902, NCT01509300
NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 65
Sponsor: Other
Protocol IDs: 2012-0708, NCI-2013-02183, RP110553 05-07-04832, P01 - 5P01, NCT01904136
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 1 to 80
Sponsor: Other
Protocol IDs: 2014-0150, NCT02423915
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: NHLBI
Protocol IDs: CDR0000066610, NHLBI-97-H-0196, NCT00003553
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, P30CA015704, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 1840.00, NCI-2009-01594, P30CA015704, P01CA018029-37A1, FHCRC-1840.00, 5910, NCT00104858
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Phase: Phase II
Type: Treatment
Status: Active
Age: 45 and under
Sponsor: Other
Protocol IDs: 2005LS043, UMN-MT2005-10, UMN-0507M71475, UMN-2005LS043, UMN-BMT-MT2005-10, NCT00309842
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2001LS058, UMN-MT2001-10, 0108M06725, UMN-2001LS058, NCT00303719
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2005LS036, UMN-MT-2005-02, UMN-0507M70121, UMN-2005LS036, NCT00305682
Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor
Phase: Phase II
Type: Treatment
Status: Active
Age: 50 to 70
Sponsor: Other
Protocol IDs: RMBMT-124-A, NCT00304720
Start Over